| Literature DB >> 25045552 |
Kana N Miyata1, Hiromi Kihira2, Manabu Haneda2, Yasuhide Nishio2.
Abstract
We report two cases of Japanese men who presented with proteinuria, eosinophilia, hypocomplementemia, and high serum immunoglobulin G4 (IgG4) concentration and were diagnosed with membranous nephropathy associated with IgG4-related tubulointerstitial nephritis on renal biopsy. The typical renal lesions of IgG4-related disease are tubulointerstitial nephritis, which improves remarkably with steroid therapy, and occasional glomerular changes. In our two cases, renal biopsy revealed IgG4-positive immune complex deposits in glomeruli in a pattern of membranous nephropathy and concurrent tubulointerstitial nephritis with IgG4 plasma cells. In both cases, proteinuria persisted with initial prednisolone treatment and was resolved only after the addition of mizoribine. We report the first two cases in which the combination of prednisolone and mizoribine was effective for treating membranous nephropathy associated with IgG4-related tubulointerstitial nephritis.Entities:
Year: 2014 PMID: 25045552 PMCID: PMC4089550 DOI: 10.1155/2014/678538
Source DB: PubMed Journal: Case Rep Nephrol ISSN: 2090-665X
Laboratory findings.
| Case 1 | Case 2 | |
|---|---|---|
| Urinalysis; protein/blood | 3+/3+ | 2+/2+ |
| Urinary protein (g/day) | 1.4 | 2.73 |
| Urinary | 11,080 | 858 (ref, 0–230) |
| Urinary NAG (U/L) | 31.9 | 151.2 (ref, 0–11.5) |
| Creatinine (mg/dL) | 1.0 | 0.9 |
| CCr (mL/min) | 92.4 | 49.1 |
| BUN (mg/dL) | 15.4 | 16.1 |
| WBC (Eosinophil) (×109/L) (%) | 11.5 (47.5) | 7.4 (46.5) |
| Hemoglobin (g/dL) | 11.9 | 9.5 |
| Hematocrit (%) | 35.4 | 28.5 |
| Total protein (g/dL) | 9.3 | 7.6 |
| Albumin (g/dL) | 2.2 | 1.7 |
| AST (U/L) | 27 | 43 |
| ALT (U/L) | 15 | 33 |
| ALP (U/L) | 492 | 480 |
| Bilirubin, total (mg/dL) | 0.4 | 0.4 |
| Amylase (U/L) | 60 | N/A |
| CRP (mg/dL) | 1.7 | 0.4 |
| CH50 (U/mL) | <5 | <5 (ref, 25–48) |
| C3 (mg/dL) | 39 | 21 (ref, 86–160) |
| C4 (mg/dL) | 2.0 | <2 (ref, 17–45) |
| Antinuclear antibody | 1 : 320 (Homo/Spec) | <1 : 40 |
| Anti-dsDNA antibody | Negative | Negative |
| Anti-Sm antibody | Negative | Negative |
| Anti-RNP antibody | Negative | 16.0 |
| Anti-SSA antibody | Negative | Negative |
| Anti-SSB antibody | Negative | N/A |
| ANCA | Negative | Negative |
| IgA (mg/dL) | 183 | 386 (ref, 110–410) |
| IgM (mg/dL) | 37 | 468 (ref, 83–190) |
| IgE (mg/dL) | 413 | 1811 (ref, 0–202) |
| IgG (mg/dL) | 6989 | 6350 (ref, 870–1700) |
| IgG1 (mg/dL) | 1710 | 2460 (ref, 423–1080) |
| IgG2 (mg/dL) | 2280 | 1740 (ref, 265–931) |
| IgG3 (mg/dL) | 249 | 1100 (ref, 5–121) |
| IgG4 (mg/dL) | 2750 | 1050 (ref, 4–108) |
| S-IL2 receptor (U/mL) | 3912 | 3973 (ref, 190–650) |
| SPEP | Normal | Normal |
| Cryoglobulin | Negative | Negative |
Note: Conversion factors for units: Creatinine in mg/dL to μmol/L, ×88.4; CCr in mL/min to mL/s, ×0.01667; BUN in mg/dL to mmol/L, ×0.357; Hemoglobin, Total protein, and Albumin in g/dL to g/L, ×10; Bilirubin in mg/dL to mol/L, ×17.1; CRP in mg/dL to mg/L, ×10; IgA, IgM, IgE in mg/dL to mg/L, ×10; IgG, IgG1, IgG2, IgG3, and IgG4 in mg/dL to g/L, ×0.01. No conversion necessary for C3, C4 in mg/dL and g/L.
Abbreviations and definitions: β2MG, β2 microglobulin; NAG, N-acetyl-beta-D-glucosaminidase; CCr, creatinine clearance; WBC, white blood cell; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; CRP, C-reactive protein; ANCA, antineutrophil cytoplasmic antibody; IgA, immunoglobulin A; S-IL2 receptor, soluble interleukin-2 receptor; SPEP, serum protein electrophoresis; ref, reference range.
Figure 1Representative microscopic histology. (a) Patchy infiltration of inflammatory cells and fibrosis in the interstitium with a clear border. Case 1. Masson trichrome stain, ×40. (b) Case 2. Masson trichrome stain, ×40. (c and d) Predominant infiltration of lymphocytes, plasma cells, and eosinophils into the interstitium. Case 1. H&E stain, ×400. (e) IgG4-positive plasma cells in the interstitium. Case 2. IgG4 immunoperoxidase stain, ×400. (f) Granular capillary wall staining for IgG. Case 1. Immunofluorescence, ×200. (g) IgG staining along the glomerular basement membrane (GBM). Case 1. IgG immunoperoxidase stain, ×400. (h) Weakly positive IgG4 staining along the GBM. Case 1. IgG4 immunoperoxidase stain, ×400. (i) Thickened GBM with spikes. Case 1. Periodic acid silver-methenamine stain, ×400. (j) Subepithelial electron-dense deposits. Case 1. ×20,000. (k) Subepithelial and mesangial electron-dense deposits. Case 2. ×10,000. (l) Scattered tubular basement membrane deposits. Case 2. ×4,000.
Treatment and the effect of IgG4-related membranous nephropathy reported in previous studies.
| Case | References, Year | Age | Gender | IgG4/IgG | TIN | S-Cr (mg/dL) | U-pro (g/day) | f/u (months) | Treatment | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| (years) | (mg/dL) | Pre Tx | Post Tx | Pre Tx | Post Tx | ||||||
| 1 | Uchiyama-Tanaka et al. 2004 [ | 64 | Male | 665/5410 | yes | 4.5 | 1.5 | 1.5 | 0.1 | 2 | mPSL |
| 2 | Watson et al. 2006 [ | 67 | Male | 2125/7070 | yes | 3.4 | 2.4 | 2.4 | 2.5 | 7 | PSL |
| 3 | Saeki et al. 2009 [ | 83 | Male | 924/3144 | yes | 1.48 | 1.22 | 2.3 | 1.6 | 4 | PSL |
| 4 |
Saida et al. 2010 [ | 78 | Male | 1860/3731 | yes | 6.17 | HD | 1.38 | HD | NA | PSL |
| 5 | Palmisano et al. 2010 [ | 68 | Male | NA | no | 1.2 | NA | 1.5 | 0.45 | NA | ACEI, statins |
| 6 | Raissian et al. 2011 [ | 75 | Male | NA | yes | 6.6 | 2.5 | 16 | NA | 1.1 | PSL |
| 7 |
Raissian et al. 2011 [ | 67 | Female | 531/1581 | yes | 1.2 | 1.3 | 4 | 0.2 | 7 | PSL |
| 8 | Cravedi et al. 2011 [ | 54 | Male | 730/2022 | no | 1.15 | NA | 7.3 | 8 | 11 | PSL, Rituximab |
| 9 | Kawano et al. 2011 [ | NA | NA | NA | yes | NA | NA | NA | NA | NA | NA |
| 10 | Yamaguchi et al. 2012 [ | 60 | Female | 142/1706 | yes | 1.05 | NA | 14 | NA | NA | NA |
| 11 | Yamaguchi et al. 2012 [ | 64 | Male | 260/4292 | yes | 1.4 | NA | 0.67 | NA | NA | NA |
| 12 | Jindal et al. 2012 [ | 72 | Male | 750/1511 | yes | 4.7 | HD | 15 | HD | NA | PSL, Rituximab |
| 13 | Alexander et al. 2013 [ | 75 | Male | NA | yes | 6.6 | 2.5 | 16 | 3.1 | 6 | PSL |
| 14 | Alexander et al. 2013 [ | 53 | Male | NA | no | 0.8 | 0.8 | 16 | 3.1 | 46 | PSL, MMF |
| 15 | Alexander et al. 2013 [ | 50 | Male | NA | no | 1.3 | 1.3 | 3.5 | 1.5 | 20 | ACEI/ARB, Rituximab, MMF |
| 16 | Alexander et al. 2013 [ | 46 | Female | NA | yes | NA | Transplant | Nephrotic | 0 | 184 | none |
| 17 | Alexander et al. 2013 [ | 67 | Male | NA | yes | 1.8 | 1.4 | 4.5 | 0.7 | 7 | PSL, Cy, ACEI |
| 18 | Alexander et al. 2013 [ | 65 | Female | NA | yes | 0.7 | 0.8 | 8.5 | 2.6 | 4 | PSL, MMF |
| 19 | Alexander et al. 2013 [ | 64 | Male | NA | yes | 3.4 | NA | 1.7 | NA | NA | NA |
| 20 | Alexander et al. 2013 [ | 34 | Male | NA | no | 1.6 | NA | 12.4 | NA | NA | NA |
| 21 | Li et al. 2014 [ | 55 | Male | 1926/5305 | yes | 0.8 | NA | 5.5 | 0.2 | 20 | PSL |
| 22 | Miyata et al. 2014 (Case 1) | 69 | Male | 2750/6989 | yes | 1.0 | 1.17 | 1.4 | 0 | 48 | PSL, MZR, AZA |
| 23 | Miyata et al. 2014 (Case 2) | 80 | Male | 1050/6350 | yes | 0.9 | 0.78 | 2.73 | 0 | 17 | PSL, MZR |
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; AZA, Azathioprine; Cy, cyclophosphamide; f/u, follow up; HD, hemodialysis; mPSL, methylprednisolone; MMF, Mycophenolate mofetil; MZR, mizoribine; PSL, prednisone/prednisolone; S-Cr, NA, not applicable; serum creatinine; TIN, tubulointerstitial nephritis; U-Pro, urine protein.